TM4SF1 Knockout PANC-1 Cell Line

Product Type:
In Stock Cell Lines
Species:
Homo sapiens (Human)
Tissue Source:
Pancreas
Disease:
Epithelioid carcinoma
Host Cell:
PANC-1
Gene Name:
TM4SF1
Inquire Now
✓ In stock
🚚 Ships next business day
Ask a Question

The TM4SF1 Knockout PANC-1 Cell Line is a CRISPR/Cas9-edited knockout cell line derived from the human pancreatic ductal adenocarcinoma cell line PANC-1, designed to disrupt TM4SF1 gene expression. TM4SF1 is a transmembrane scaffold protein that promotes integrin-mediated adhesion and signaling, activating downstream kinases such as FAK, Src, ERK1/2, and AKT, and is implicated in tumor cell proliferation, migration, and angiogenesis. This loss-of-function model allows detailed investigation of TM4SF1-dependent mechanisms in pancreatic cancer, including its roles in metastasis, drug resistance, and tumorigenesis. It is suitable for a range of assays, from biochemical analysis to in vivo xenograft studies. For more information or to acquire this cell line, please contact Ascent Research.

Shipping Info: Cryopreserved in vials and shipped on dry ice

Disclaimer: For Research Use Only
Host CellPANC-1
Sex of DonorMale
Age56 years
Gene NameTM4SF1
Gene IdentifierNCBI Gene ID 4071
MorphologyEpithelial-like
Growth ModeAdherent
StorageLiquid nitrogen (LN2)
Temperature37°C
Atmosphere5% CO₂
Sterility testingThe bacterial, yeast, and fungi are not detected in these cells by daily monitor.
Mycoplasma testingNegative for mycoplasma through PCR analysis

Intended Use: This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

Disclaimer: Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability.

By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use.

This product is provided "AS IS". For Research Use Only. Not for human or animal therapeutic use.

Description

The TM4SF1 Knockout PANC-1 Cell Line is a CRISPR/Cas9-edited knockout cell line in which the TM4SF1 gene has been disrupted to establish a loss-of-function model for studying the molecular mechanisms underlying pancreatic ductal adenocarcinoma. This engineered cell line is derived from the well-characterized PANC-1 parental line and offers a defined genetic background for interrogating TM4SF1-dependent signaling events. The knockout was generated using CRISPR/Cas9-mediated gene disruption, resulting in stable ablation of TM4SF1 expression, and serves as a critical tool for functional genomics and cancer biology research.

PANC-1 is a human pancreatic ductal adenocarcinoma cell line originally established from a primary tumor of the pancreas. It exhibits an epithelial morphology and retains key genetic features typical of pancreatic cancer, making it a widely utilized model for investigating tumor cell biology, including proliferation, invasion, and therapeutic resistance. This cell line is particularly valuable for dissecting signaling pathways that drive pancreatic cancer progression, and the TM4SF1 knockout derivative extends its utility for mechanistic studies focused on tetraspanin-mediated cellular processes.

TM4SF1 (Transmembrane 4 L Six Family Member 1) is a tetraspanin protein that functions as a molecular scaffold, facilitating the organization of protein complexes at the cell surface. It interacts with integrin ??1, integrin ??3, integrin ??6, CD44, and EGFR, and is activated by upstream regulators such as SP1, TGF-??, hypoxia, and EGF. Upon ligand engagement, TM4SF1 promotes integrin-mediated adhesion and signaling, leading to phosphorylation of FAK and Src, which in turn activate downstream effectors including ERK1/2 and AKT. This cascade enhances cell proliferation, migration, and survival, while also upregulating VEGF to stimulate tumor angiogenesis. TM4SF1 is implicated in multiple pathways, including integrin-mediated cell adhesion, FAK signaling, angiogenesis, and Wnt/??-catenin signaling, with representative components such as p130Cas, paxillin, VEGFR2, and eNOS contributing to its functional network.

In the context of pancreatic cancer, TM4SF1 is frequently overexpressed and correlates with aggressive disease characteristics. The TM4SF1 Knockout PANC-1 Cell Line therefore provides a physiologically relevant platform to dissect the contribution of TM4SF1 to pancreatic tumorigenesis. By comparing knockout and wild-type PANC-1 cells, researchers can elucidate how TM4SF1 modulates integrin-dependent signaling, cytoskeletal dynamics, and pro-angiogenic factor secretion. This model is instrumental for uncovering the mechanistic basis of TM4SF1-driven tumor progression and for evaluating the impact of its loss on key malignant phenotypes in a pancreatic ductal adenocarcinoma background.

This cell line supports a broad array of experimental applications, including functional studies of TM4SF1 in cell proliferation (MTT or BrdU assays), migration (Transwell or wound healing), invasion, and apoptosis. It can be employed in phospho-protein signaling arrays to map altered kinase activities, immunofluorescence to assess integrin localization, co-immunoprecipitation to probe TM4SF1-interacting complexes, and xenograft tumor growth assays to evaluate in vivo tumorigenicity. Additionally, it is suitable for drug resistance investigations and angiogenesis research, with validation via Western blotting, RT-qPCR, and Sanger sequencing of the CRISPR target site. For further technical information or to obtain this product, please contact Ascent Research.